Establishment and innovative practice of Integrative System of Prevention, Diagnosis and Management for echinococcosis in China

doi:10.12140/j.issn.1000-7423.2019.04.003

Abstract

Abstract:

Echinococcosis (hydatid disease) is a neglected tropical zoonotic disease caused by the infection of Echinococcus larvae. It prevails globally and China has the highest disease burden of two main types of echinococcosis including cystic echinococcosis (CE) and alveolar echinococcosis (AE). The hydatid disease is a big threat of public health and a heavy burden of economic lose in China. The AE cases in western China account for over 90% of the total AE cases in the world. Great achievements have been made in the control and treatment of the diseases since the founding of People’s Republic of China, including remarkable improvement in clinical cure rate, significant reduction in morbidity and mortality in humans and infections in animals. China has made inspiring achievements in the research of the genomics, molecular epidemiology, immunology, diagnostic tools, treatment approaches, prevention strategies and vaccine development of echinococcosis especially since the beginning of the 21th century. This paper mainly described and discussed the establishment and innovative practice of Integrative System of Prevention, Diagnosis and Management for echinococcosis in China, which includes systems for scientific prevention and control, standardized diagnosis, innovative surgery and treatment, and relevant research and translational application.

Key words: Echinococcosis, Scientific prevention, Standardized diagnosis, Innovative surgery, Medication, Research and translation

CLC Number:

R532.32

Aini ABUDUSALAMU, Ying-mei SHAO, Aji TUERGANAILI, Wen-bao ZHANG, Ren-yong LIN, Yan-yan HOU, Zhuang-zhi ZHANG, Hao WEN. Establishment and innovative practice of Integrative System of Prevention, Diagnosis and Management for echinococcosis in China[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2019, 37(4): 388-394.

Figures/Tables 3

References 36

[1]	Deplazes P, Rinaldi L, Alvarez Rojas CA, et al. Global distribution of alveolar and cystic echinococcosis[J]. Adv Parasitol, 2017, 95: 315-493.
[2]	中国医师协会外科医师分会包虫病外科专业委员会. 肝两型包虫病诊断与治疗专家共识(2019版)[J]. 中华消化外科杂志, 2019, 18(8): 711-721.
[3]	Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: advances in the 21st century[J]. Clin Microbiol Rev, 2019, 32(2): e00075-e00018.
[4]	Torgerson PR, Schweiger A, Deplazes P,et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years[J]. J Hepatol, 2008, 49(1): 72-77.
[5]	Brunetti E, Kern P, Vuitton DA, et al. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans[J]. Acta Trop, 2010, 114(1): 1-16.
[6]	伍卫平, 王虎, 王谦, 等. 2012-2016年中国棘球蚴病抽样调查分析[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(1): 1-14.
[7]	段新宇, 魏晶晶, 王乐, 等. 新疆基层医院包虫病住院患者直接经济负担分析[J]. 实用预防医学, 2015, 22(10): 1164-1166.
[8]	祖丽菲耶·艾则孜. 自体肝移植治疗终末期肝泡型包虫病患者疾病经济负担研究[D]. 乌鲁木齐: 新疆医科大学, 2017.
[9]	李军, 郭刚, 张壮志, 等. 棘球绦虫的主要生理学特点与包虫病控制方法的确立[J]. 中华预防医学杂志, 2018, 52(2): 210-214.
[10]	Anderson FL, Chai JJ, Liu FJ.Prevalence of Echinococcus granulosus in dogs in the Xinjiang Uygur Autonomous Region, Prc. Compendium on cystic echinococcosis with special reference to the Xinjiang Uygur Autonomous Region, People’s Republic of China[M]. Utah: Bringham Young University print service, 1993: 5-7.
[11]	王国强. 全国包虫病流行情况调查报告[M]. 上海: 上海科学技术出版社, 2016: 17.
[12]	Jenkins DJ.WHO/OIE manual on echinococcosis in humans and animals: a public health problem of global concern[J]. Int J Parasitol, 2001, 31(14): 1717-1718.
[13]	McManus DP, Gray DJ, Zhang WB, et al. Diagnosis, treatment, and management of echinococcosis[J]. BMJ, 2012, 344: e3866.
[14]	Kern P.Clinical features and treatment of alveolar echinococcosis[J]. Curr Opin Infect Dis, 2010, 23(5): 505-512.
[15]	Stojković M, Weber TF, Junghanss T.Clinical management of cystic echinococcosis: state of the art and perspectives[J]. Curr Opin Infect Dis, 2018, 31(5): 383-392.
[16]	Brumpt E, Blagosklonov O, Calame P, et al. AE hepatic lesions: correlation between calcifications at CT and FDG-PET/CT metabolic activity[J]. Infection, 2019, DOI:10.1007/s15010-019-01328-z.
[17]	Ahn CS, Han XM, Bae YA, et al. Alteration of immunoproteome profile of Echinococcus granulosus hydatid fluid with progression of cystic echinococcosis[J]. Parasit Vectors, 2015, 8: 10.
[18]	Zeghir-Bouteldja R, Polomé A, Bousbata S, et al. Comparative proteome profiling of hydatid fluid from Algerian patients reveals cyst location-related variation in Echinococcus granulosus[J]. Acta Trop, 2017, 171: 199-206.
[19]	Hernández-González A, Santivañez S, García HH, et al. Improved serodiagnosis of cystic echinococcosis using the new recombinant 2B2t antigen[J]. PLoS Negl Trop Dis, 2012, 6(7): e1714.
[20]	Vuitton DA, Gottstein B.Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay[J]. J Biomed Biotechnol, 2010, 2010: 923193.
[21]	Valot B, Rognon B, Prenel A, et al. Screening of antigenic vesicular fluid proteins of Echinococcus multilocularis as potential viability biomarkers to monitor drug response in alveolar echinococcosis patients[J]. Proteomics Clin Appl, 2017, 11(11/12).
[22]	Knapp J, Umhang G, Poulle ML, et al. Development of a real-time PCR for a sensitive one-step coprodiagnosis allowing both the identification of carnivore feces and the detection of Toxocara spp. and Echinococcus multilocularis[J]. Appl Environ Microbiol, 2016, 82(10): 2950-2958.
[23]	Aliakbarian M, Tohidinezhad F, Eslami S, et al. Liver transplantation for hepatic alveolar echinococcosis: literature review and three new cases[J]. Infect Dis (Lond), 2018, 50(6): 452-459.
[24]	Piarroux M, Piarroux R, Giorgi R, et al. Clinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patients[J]. J Hepatol, 2011, 55(5): 1025-1033.
[25]	Koch S, Bresson-Hadni S, Miguet JP, et al. Experience of liver transplantation for incurable alveolar echinococcosis: a 45-case European collaborative report[J]. Transplantation, 2003, 75(6): 856-863.
[26]	Bresson-Hadni S, Blagosklonov O, Knapp J, et al. Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study[J]. Liver Transpl, 2011, 17(7): 855-865.
[27]	Pichlmayr R, Bretschneider HJ, Kirchner E, et al. Ex situ operation on the liver. A new possibility in liver surgery[J]. Langenbecks Arch Chir, 1988, 373(2): 122-126.
[28]	Wen H, Dong JH, Zhang JH, et al. Ex vivo liver resection followed by autotransplantation for end-stage hepatic alveolar echinococcosis[J]. Chin Med J, 2011, 124(18): 2813-2817.
[29]	温浩, 董家鸿, 张金辉, 等. 体外肝切除联合自体肝移植治疗肝泡型包虫病[J]. 中华消化外科杂志, 2011, 10(2): 148-149.
[30]	季学闻, 张金辉, 于湘友, 等. 自体肝移植治疗终末期肝泡型包虫病一例[J]. 中华消化外科杂志, 2015, 14(2): 157-158.
[31]	Wen H, Dong JH, Zhang JH, et al. Ex vivo liver resection and autotransplantation for end-stage alveolar echinococcosis: a case series[J]. Am J Transplant, 2016, 16(2): 615-624.
[32]	吐尔干艾力·阿吉, 邵英梅, 赵晋明, 等. 肝泡型包虫病自体肝移植中提升功能肝“量与质”的临床实践: 附12例临床病例分析[J]. 中华医学杂志, 2017, 97(4): 270-275.
[33]	Aji T, Dong JH, Shao YM, et al. Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis[J]. J Hepatol, 2018, 69(5): 1037-1046.
[34]	Kern P, Wen H, Sato N, et al. WHO classification of alveolar echinococcosis: principles and application[J]. Parasitol Int, 2006, 55(Suppl): S283-S287.
[35]	Wang J, Jebbawi F, Bellanger AP, et al. Immunotherapy of alveolar echinococcosis via PD-1/PD-L1 immune checkpoint blockade in mice[J]. Parasite Immunol, 2018, 40(12): e12596.
[36]	Zhang C, Lin R, Li Z, et al.Immune exhaustion of T cells in alveolar echinococcosis patients and its reversal by blocking checkpoint receptor TIGIT in a murine model[J]. Hepatology, 2019, DOI:10.1002/hep.30896.